FFC/TFCF – Phase 2

Task Force for Cystic Fibrosis

FFC/TFCF – Phase 2

The main objective of the Task Force for Cystic Fibrosis project is to develop new correctors and enhancers for the F508del mutation and, potentially, for other CF mutations. The project, which is expected to last three and a half years, is divided into three phases: 1) Hit identification; 2) Hit-to-lead; 3) Lead optimisation.
€ 0 still needed
0%
€ 370.000 goal

pRINCIPAL INVESTIGATOR

Luis Galietta (Lab. Genetica Molecolare, Ist. G. Gaslini, Genova)

Partner

Tiziano Bandiera (Dip.to Drug Discovery, Istituto Italiano Tecnologia, IIT, Genova)

Researchers

20

Category

AREA 4 Lung inflammation

Duration

1 year

Goal

€ 370.000

Funds raised

€ 370.000

Objectives

The first phase of the project has shown very promising results. A group of compounds with CFTR-DF508 corrector potential comparable to or greater than that of known correctors has been identified. Some highly significant potentiators have also been identified. Based on these results, FFC Ricerca has decided to proceed to Phase II, securing the necessary funding.

In the second phase, the hit-to-lead phase (from the initial active compound to the lead compound), which will last one year (from March 2015 to February 2016), the work of the IIT chemists will begin. For each initial active compound (hit), analogous compounds will be generated, in which various types of minor modifications will be made to the initial chemical structure. The new compounds, in groups of 20-30, will be tested on cells in the Gaslini laboratory to determine which of the modifications has had a potentially beneficial effect on the compound’s activity. These results will be crucial in guiding the synthesis of new compounds at the IIT, in the search for modulators and potentiators with progressively improved characteristics.

Project continues in Phase 3.

who adopted the project

Energy T.I. Group S.p.A. Milano

€ 35.000

LIFC Ass. Siciliana in ricordo di Davide Radicello

€ 40.000

Danone Italia

€ 35.000

OTHER PROJECTS

Discover the other projects

FFC/TFCF – Preclinical phase

The Task Force for Cystic Fibrosis project has identified new compounds that are highly active in vitro in correcting the CFTR protein. Among them, the most potent and promising compound, ARN23765, has been selected for preclinical development, an essential step towards its potential use in clinical trials in humans.

FFC Ricerca 2025 strategic project: De-risking GY

Assessing the safety and clinical potential of GY971, an anti-inflammatory compound for cystic fibrosis

FFC Ricerca 2025-2028 strategic project: MindKids-CF

Development of screening and monitoring tools for anxiety, depression, and behavior Problems in Italian Children with Cystic Fibrosis under 12 Years of Age